Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi®a highly purified, doubly inactivated FVIII/VWF concentrate
| Autor: | Víctor Jiménez-Yuste, Fernando Hernandez-Navarro, R. Fernandez‐Morata, M. T. Alvarez, Manuel Quintana |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Adolescent Blood Loss Surgical Hemorrhage Body weight Young Adult Von willebrand Von Willebrand factor hemic and lymphatic diseases von Willebrand Factor medicine Von Willebrand disease Humans In patient Clinical efficacy Child Desmopressin Genetics (clinical) Aged Retrospective Studies Aged 80 and over Bleeding episodes Factor VIII biology business.industry Hematology General Medicine Middle Aged medicine.disease Hemostasis Surgical Surgery Drug Combinations von Willebrand Diseases Treatment Outcome Child Preschool biology.protein Drug Evaluation Virus Inactivation Female business medicine.drug |
| Zdroj: | Haemophilia. 14:963-967 |
| ISSN: | 1365-2516 1351-8216 |
| Popis: | Summary. Therapy with factor VIII/von Willebrand factor (FVIII/VWF) concentrate is the mainstay therapy in patients with von Willebrand disease (VWD) unresponsive to desmopressin. There are several commercially available FVIII/VWF concentrates that have been tested in VWD patients. We retrospectively analized the clinical efficacy in bleeding episodes and surgery of a highly purified FVIII/VWF complex with two inactivation steps (Fanhdi®) in VWD patients. Sixty patients were included in the study. Treatment schedule consisted of one or more doses (standard dose 40 IU/kg body weight of FVIII) of Fanhdi®. One hundred and fifty bleeding episodes were treated. These were: 28 serious bleedings; 92 moderate and 30 mild. An excellent clinical efficacy in almost 95% of cases was observed. Fanhdi® was administered during 66 surgical procedures (38 major and 28 minor) with an overall efficacy of 98%. Fanhdi® a highly purified, doubly virus-inactivated FVIII/VWF concentrate, with a high content of active VWF and an excellent record of clinical safety, is a valid choice in treating VWD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|